BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.7%

Neg 0% Neu 92.7% Pos 0%

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.

Comments

No comments yet. Be the first!